Company

Stephen A. Sherwin, M.D.
Co-founder & Chairman, Board of Directors

Dr. Sherwin has served as Chief Executive Officer and a Director of Cell Genesys, Inc. since 1990 and as Chairman of the Board of Cell Genesys since 1994.  From 1983 to 1990, Dr. Sherwin held various positions at Genentech, Inc., most recently as Vice President, Clinical Research. Prior to 1983 he was on the staff of the National Cancer Institute.  Dr Sherwin currently serves as a Director of Neurocrine Biosciences, Inc. and Rigel Pharmaceuticals, Inc., and is the Treasurer and a Director of the Biotechnology Industry Organization. He was also a Co-founder and former Chairman of Abgenix, Inc. Dr. Sherwin received his B.A. from Yale University and his M.D. from Harvard Medical School and is board certified in internal medicine and medical oncology.

back to top

Jeffrey M. Ostrove, Ph.D.
President & Chief Executive Officer

Prior to joining Ceregene as its first employee in April 2001, Dr. Ostrove was Chief Operating Officer of NeuroVir Therapeutics, Inc. located in Vancouver, B.C. and San Diego, CA and was instrumental in its merger with Medigene AG. Preceding NeuroVir (Medigene), Dr. Ostrove served as Senior Vice President and Chief Scientist of MAGENTA Corporation of Rockville, Maryland, a company he founded as a subsidiary of BioReliance, Inc. where he was also Vice President for Scientific Development. Dr. Ostrove also served on the staff of the National Institute of Allergy and Infectious Disease (NIAID) at the National Institutes of Health. Dr. Ostrove holds a Ph.D. in molecular biology from the University of Florida College of Medicine and completed his post-doctoral training at The Johns Hopkins University School of Medicine.

back to top

Mark Tuszynski, M.D., Ph.D.
Co-founder; Professor of Neurosciences, University of California, San Diego Director, Center for Neural Repair and Attending Neurologist VA Medical Center, La Jolla, California

Dr. Tuszynski has performed pioneering research in gene therapy, growth factor biology, aging, Alzheimer's disease and spinal cord regeneration. He is an author of over 100 publications, and has received the Silvio O. Conte Neuroscience Research Award from the American Academy of Neurology, the Bernard Sanberg Award for neural regeneration research from the American Society for neural transplantation and repair, the Ariens Kappers Award from the Netherlands Institute for Brain Research, the National Paralysis Foundation Spinal Cord Injury Research Award, the Barbara Haugh Alzheimer's Disease Research Award, and the Visionary Award from the Alzheimer's Association of San Diego. He serves on the editorial boards of Experimental Neurology and Neurobiology of Disease. Dr. Tuszynski received his B.S. in biology and M.D. from the University of Minnesota, and his Ph.D. in neurosciences from UCSD. He completed his neurology residency at Cornell University Medical Center.

back to top

David Mack, Ph.D.
Director, Alta Partners

Dr. Mack joined Alta in 2002. Prior to Alta, he co-founded and served as Vice President of Genomics Research at Eos Biotechnology (acquired by Protein Design Labs in 2003). From 1995 to 1997, he served at Affymetrix as Head of Cancer Biology where he oversaw the development and application of DNA array technology in the areas of oncology and inflammation. Dr. Mack was also a pivotal member of the Polymerase Chain Reaction (PCR) invention group at Cetus (now Chiron) in the mid 1980s. He has co-authored more than 30 scientific articles and reviews including papers published in Cell, Science and Nature, and is an inventor on 21 US patents. Dr. Mack was an American Cancer Society postdoctoral fellow at Stanford University School of Medicine in Microbiology and Immunology. He received his Ph.D. in 1992 from the University of Chicago where he was a Howard Hughes Fellow in molecular genetics and cell biology. Dr. Mack holds a Bachelor of Arts in Molecular Biology from the University of California, Berkeley.

back to top

Dennis Henner, Ph.D.
General Partner, MPM BioVentures III

Prior to joining MPM, Dr. Henner was at Genentech from 1981 to 2001. He was the Senior Vice President of Research at Genentech and a member of the Executive Committee, Product Review Committee and Research Review Committee. During his tenure, he oversaw the development of numerous products that have been fundamental to the success of Genentech including novel antibody products such as Herceptin. Dr. Henner is currently Director of Tercica, Rinat Neuroscience, Synergia, Ceregene and Kalobios. His scientific work focused on the expression of therapeutic proteins in bacterial hosts, and the development of recombinant antibody therapeutics. Dr. Henner received his Ph.D. in microbiology at the University of Virginia and did postgraduate training at the Scripps Clinic and Research Foundation.

back to top

John Walker
Board Director

Mr. Walker is currently the Chairman and Interim CEO at Novacea, a publicly traded Biotech company with a Phase III program in development for the treatment of Prostate Cancer. In addition he serves as Chairman of Renovis, and as a board of directors member at Affymax and Geron, all publicly traded companies. Mr. Walker is also on the board of directors of several private companies, including Kai, Guava and Aerovance.

back to top

Liza Page Nelson
Managing Director, Investor Growth Capital, Inc.

Ms. Nelson joined Investor Growth Capital in 1998, where she is Co-Head of the firm’s Healthcare group. Prior to IGC, she spent 10 years with Pfizer, where she held various positions in finance, strategy, contracting, marketing, business development and operating management. This included co-founding and leading Pfizer’s healthcare services business. Prior to Pfizer, she was with The Boston Consulting Group and Warburg, Pincus, where in both cases she focused on healthcare and life science companies. Ms. Nelson currently serves on the Boards of Ception Therapeutics, Epigenesis Pharmaceuticals and Solstice Neurosciences. Ms. Nelson holds an M.B.A. in Finance and Marketing from the Yale School of Management and a B.A. in Economics from Wesleyan University in Middletown, Connecticut.

back to top